SUBSTANCES IN ORDER TO ACHIEVE PREFERENCE AND CREATE ACCEPTANCE

Abstract: The present invention relates to the use of substances with oxytocin activity in order to achieve preference and create acceptance. It also relates to a composition comprising at least one substance with oxytocin activity in order to achieve preference and/or create acceptance. It also relates to a composition containing at least one substance with oxytocin activity and at least one flavouring or fragrance agent in order to create acceptance.

Description: Substances in order to achieve preference and create acceptance The present invention relates to the use of substances with oxytocin activity in order to achieve preference and create acceptance. It also relates to a composition comprising at least one substance with oxytocin activity in order to achieve preference and/or create acceptance. It also relates to a composition containing at least one substance with oxytocin activity and at least one flavouring or fragrance agent in order to create acceptance. Background of the invention Peptide hormones are substances naturally occurring in the body consisting of seve- ral amino acids. Such a peptide hormone is oxytocin. As a hormon this has a contraction developing effect on the smooth muscle in the uterus in mammals, wherein delivery is facilitated, as well as the muscles in milk glands, wherein milk ejection and milk production are facilitated. As a central stimulating substance oxytocin plays an important role in the interaction between mother and progeny in mammals. Ac- cordingly, the oxytocin production in the mother results in acceptance and preference of her kid. This hormone is also important in order to a mammal kid being recognized by its mother, which results in that the kid searches and follows her. It has now been shown that oxytocin could be used, optionally, together with a flavouring or fragrance agent in different compositions in order to achieve preference and cre- ate acceptance. In comparison between perfumes with and without addition of oxytocin, respectively, in a number of subjects of an experiment, most of them prefer perfume with oxytocin added. WO 95/01368 describes a procedure for preparation of cyclic pep des with disulfide groups, which procedure simplifies the synthesis and lowers the production costs. This procedure is useful in the preparation of oxytocin and vasopressin, and the corresponding derivatives and analogues thereof. EP-A-689 452 describes a solid pharmaceutical composition for oral administration of small and medium-sized peptides, especially oxytocin, vasopressin and analogues thereof, and comprises, besides the peptide, a protease inhibitor, an enteric coating, and a pharmaceutically acceptable carrier. WO 92/11287 describes new vasopressin and vasotocin derivatives. These derivatives have a strong affinity to oxytocin and Vj -vasopressin derivatives and are useful for the preparation of medicaments. However, none of these known publications describes the use of oxytocin in order to achieve preference and create acceptance. Summary of the invention The present invention relates to the use of a substance with oxytocin activity in order to achieve preference and create acceptance. The invention also relates to a composition comprising an effective concentration of at least one substance with oxytocin activity, together with an adjuvant and, optionally, at least one fragrance agent or flavouring. Such a composition could be used in order to create acceptance in an animal of a progeny. It could also be used in order to achieve preference of hygienic and/or cosmetic products, and food, beverages, and stimulants etc. Detailed description of the invention An object of the present invention is the use of a substance with an oxytocin like activity in order to achieve preference between a product with and without a substance, respectively, with the oxytocin like activity and to create acceptance. Examples of substances with oxytocin activity are the following compounds: s— s- Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH 2 Oxytocin i.e. W is He, X is Gin, Y is Leu, and Z is Gly in Claim 2 and 7 I S — S 1 Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Ile-Gly-NH 2 Mesotocin i.e. W is He, X is Gin, Y is He, and Z is Gly in Claim 2 and 7 l S — S 1 Cys-Tyr-Ile-Ser-Asn-Cys-Pro-Ile-Gly-NH 2 Isotocin i.e. W is He, X is Ser, Y is He, and Z is Gly in Claim 2 and 7 l S — S 1 Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Arg-Gly-NH 2 Vasotocin i.e. W is He, X is Gin, Y is Arg, and Z is Gly in Claim 2 and 7 I S — S 1 Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH 2 Vasopressin i.e. W is Phe, X is Gin, Y is Arg, and Z is Gly in Claim 2 and 7. Other substances with oxytocin activity could also be used, such as naturally occurring or artificially modified variants, analogues, and derivatives of oxytocin, mesotocin, isotocin, vasotocin, and vasopressin. Such substances could be obtained by ad- dition, insertion, elimination, or substitution of at least one amino acid in these hormones. By substance with an oxytocin like activity is also understood precursors, metabolic derivatives, agonists, or analogues of the substances mentioned herein displaying the same properties. It could be ascertained that these variants are analogues of oxytocin, mesotocin, isotocin, or vasotocin by immunological methods, e.g. RIA (radio-immunoassay), IRMA (radiometric methods), RIST (radioimmuno- sorbent test), RAST (radioallergosorbent test). Oxytocin and vasopressin can be pro- duced e.g. according to WO 95/01368 and oxytocin according to USP 2,938,891 and 3,076,797. There is also a possibility to create new compounds with oxytocin activity by means of computer simulation. Methods for computer simulation are known by a person skilled in the art, e.g. as described in EP 0660 210 A2. Eight new compounds have been created by means of computer simulation, namely the following peptides: s— s- Cys-Tyr-Cha-Cit-Asn-Cys-Pro-Arg-Gly-NH 2 Peptide 1 i.e. W is Cha, X is Cit, Y is Arg, and Z is Gly in Claim 2 and 7 I S — S 1 Cys-Tyr-Val-Thr-Asn-Cys-Pro-Leu-Gly-NH 2 Peptide 2 i.e. W is Val, X is Thr, Y is Leu, and Z is Gly in Claim 2 and 7 I S — S 1 Cys-Tyr-Hoph-Thr-Asn-Cys-Pro-Val-Gly-NH 2 Peptide 3 i.e. W is Hoph, X is Thr, Y is Val, and Z is Gly in Claim 2 and 7 I S — S 1 Cys-Tyr-Phe-Cit-Asn-Cys-Pro-Leu-Gly-NH 2 Peptide 4 i.e. W is Phe, X is Cit, Y is Leu, and Z is Gly in Claim 2 and 7 I S — S 1 Cys-Tyr-Cha-Arg-Asn-Cys-Pro-Hos-Ala-NH 2 Peptide 5 i.e. W is Cha, X is Arg, Y is Hos, and Z is Ala in Claim 2 and 7 I S — S 1 Cys-Tyr-Val-Daba-Asn-Cys-Pro-Daba-Ala-NH 2 Peptide 6 i.e. W is Val, X is Daba, Y is Daba, and Z is Ala in Claim 2 and 7 s — S Cys-Tyr-Hoph-Daba-Asn-Cys-Pro-Cit-Ala-NH 2 Peptide 7 i.e. W is Hoph, X is Daba, Y is Cit, and Z is Ala in Claim 2 and 7 i S — S 1 Cys-Tyr-Phe-Arg-Asn-Cys-Pro-Val-Ala-NH 2 Peptide 8 i.e. W is Phe, X is Arg, Y is Val, and Z is Ala in Claim 2 and 7, wherein Cha stands for cyclohexylalanine, Hoph stands for homophenylalanine, Cit stands for citruline, Daba stands for diaminobutyric acid, and Hos stands for homoserine. The invention also relates to the peptides mentioned above in both D- and L-form. These and the peptides above can be produced by methods known to a person skilled in the art, e.g. according to Merrifield, R.B. in Streitweiser, A. & Heathcock, C.H., Introduction to Organic Chemistry, p. 949-950, 3:rd ed., 1985, Macmillan Publishing Company, New York. According to Muller, S. et al, "A retro-inverso peptide corresponding to the GH loop of foot-and-mouth disease virus elicits high levels of long-lasting protective neutralizing antibodies", Proc. Natl. Acad. Sci. USA, Vol. 94, p. 12545-12550, November 1997, the D-form is more efficient than the L-form. It could be ascertained that those compounds prepared by computer simulation have oxytocin effect by tests, such as described in the appended Examples. Preferably, oxytocin is used. Anot er object of the invention is a composition comprising an effective concentration of at least one substance med oxytocin activity, together with at least one adjuvant. An effective concentration could be determined by a person skilled in the art. The concentration of the substance with oxytocin activity could be 0.5-500 IU, espe- daily 1-100 IU. Examples of substances with oxytocin activity are oxytocin derivatives, such as oxytocin, mesotocin, isotocin, Peptide 2, Peptide 3, Peptide 4, and Peptide 8; vasopressin derivatives, such as vasotocin, vasopressin, Peptide 1, Peptide 5, Peptide 6, and Peptide 7. Examples of usable adjuvants are cosmetically, particularly pharmaceutically and veterinary medicinally acceptable adjuvants, such as wa- ter and organic solvents, e.g. alcohols, especially ethanol. By adjuvants are meant conventional adjuvants that strengthen the effect, or carrier substances. For example, such a composition could be used in order to create acceptance. An example thereof is the habituation of a cow on a milking machine. When a cow, which has recently calved, is allowed to suckle her calf, the imprinting thereof will be so strong that the cow could have some trouble in accepting a milking machine. By application of the composition hereinabove of the milking machine, the acceptance thereof by the cow could be facilitated. Another example is childrens ' weaning from their mother ' s breast when breast-feeding and conversion to a feeding bottle, and the contrary. By application of the composition hereinabove on a feeding bottle/the mother ' s breast, the acceptance thereof by the child could be facilitated. A further object of the present invention is a composition comprising an effective concentration of at least one substance with oxytocin activity, together with at least one fragrance agent and at least one adjuvant. An effective concentration could be determined by a person skilled in the art. The concentration of the substance with oxytocin activity could be 0.5-500 IU, especially 1-100 IU. Examples of substances with oxytocin activity are oxytocin derivatives, such as oxytocin, mesotocin, isotocin, Peptide 2, Peptide 3, Peptide 4, and Peptide 8; vasopressin derivatives, such as vasotocin, vasopressin, Peptide 1, Peptide 5, Peptide 6, and Peptide 7. Examples of usable substances are defined hereinabove. For example, such a composition could be used in order to create preference between a product with and without a substance with oxytocin acitivity, respectively. Examples of those products are hygienic and/or cosmetic products, such as eau-de-Cologne, eau-de-toilette, perfume, make-up, soap, shower cream, hair conditioning agents, such as shampoos, conditioning agents, creams, lotions, and ointments; stimulants, such as cigars, cigarettes, tobacco, and chewing- tobacco. The composition could also be represented by such hygienic and/or cosmetic products, whereto have been added at least one fragrance agent and at least one substance with oxytocin activity according to the invention. A further object of the invention is a composition comprising an effective concentration of at least one substance with oxytocin activity, together with at least one fla- vouring and, optionally, at least one adjuvant. An effective concentration could be determined by a person skilled in the art. The concentration of the substance with oxytocin activity could be 0.5-500 IU, especially 1-100 IU. Examples of substances with oxytocin activity are oxytocin derivatives, such as oxytocin, mesotocin, isotocin, Peptide 2, Peptide 3, Peptide 4, and Peptide 8; vasopressin derivatives, such as vasotocin, vasopressin, Peptide 1, Peptide 5, Peptide 6, and Peptide 7. Examples of usable substances are such extenders used in food, beverages, and stimulants. For example, such a composition could be used in order to create preference between a product with and without a substance with oxytocin activity, respectively. Examples of such products are food, such as sweets and snacks, beverages, such as soft drinks and alcoholic beverages, stimulants, such as cigars, cigarettes, tobacco, and chewing-tobacco. The composition could also be represented by such food, beverages, and stimulants, whereto have been added at least one flavouring and at least one substance according to the invention. The effect of oxytocin could be tested by measuring the contraction effect thereof in the uterus or the bindning of oxytocin to receptors in the uterus. These receptors are not necessarily the same as in the case to achieve preference and create acceptance. Therefore, it is suitable to measure the effect of oxytocin with a trial panel in order to ascertain these effects. The invention is illuminated by the following Examples. These Examples are only illustrative and are not intended to limit the invention in any way whatsoever. All publications mentioned herein and the priority application SE 9701184-5 are hereby incorporated by reference. By the expression "comprising" we understand including but not limited to. Thus, other non-mentioned substances, additives or carriers may be present. Examples In a trial to ascertain the effect of oxytocin a trial panel compared the odour of a pa- per sheet sprayed five times with either of the following mixtures: mixture A (Perfume Chanel, no 5) and mixture B (Perfume Chanel, no 5 + Syntocinon* in the form of a nasal spray with 4 IU oxytocin/ml nasal spray). Example 1 The trial panel consisted of 40 male students, aged 19-32 years. Every one was a non-smoker and not afflicted with a cold. Of these, 29 preferred mixture B, 8 preferred mixture A, and 3 did not notice any odour difference between mixture A and mixture B. Example 2 The trial panel consisted of 38 female students, aged 19-32 years. Every one was a non-smoker and not afflicted with a cold. Of these, 27 preferred mixture B, 10 pre- ferred mixture A, and 1 did not notice any odour difference between mixture A and mixture B. From the Examples it could be seen that addition of oxytocin creates preference in a choice between perfumes with and without oxytocin, respectively.

Claims: Claims 1. Use of a substance with oxytocin activity in order to achieve preference between a product with and without a substance with oxytocin activity, respectively, and/or in order to create acceptance. 2. Use according to Claim 1, characterized in that the substance is selected from the group consisting of the following oxytocin derivatives: wherein W is selected from the group consisting of He, Val, Hoph, and Phe, X is selected from the group consisting of Gin, Ser, Thr, Cit, and Arg, Y is selected from the group consisting of Leu, He, and Val, Z is selected from the group consisting of Gly and Ala; and the following vasopressin derivatives: wherein W is selected from the group consisting of He, Phe, Cha, Val, and Hoph, X is selected from the group consisting of Gin, Cit, Arg, and Daba, Y is selected from the group consisting of Arg, Hos, Daba, and Cit, Z is selected from the group consisting of Gly and Ala. 3. Use according to Claim 1-2, characterized in that the substance is selected from the group consisting of the following oxytocin derivatives: oxytocin, mesotocin, isotocin, Peptide 2, Peptide 3, Peptide 4, and Peptide 8; and the following vasopressin derivatives: vasotocin, vasopressin, Peptide 1, Peptide 5, Peptide 6, and Peptide 7. 4. Composition in order to create acceptance and/or preference, characterized in that it comprises an effective concentration of at least one substance with oxytocin activity, optionally, together with at least one adjuvant. 5. Composition according to Claim 4, characterized in that it comprises an effective concentration of at least one substance with oxytocin activity, together with at least one fragrance agent or flavouring and, optionally, at least one adjuvant. 6. Composition according to Claim 4-5, characterized in that the effective concentration is 0.5-500 IU, especially 1-100 IU. 7. Composition according to Claim 4-5, characterized in that the substance is selected from the group consisting of the following oxytocin derivatives: wherein W is selected from the group consisting of He, Val, Hoph, and Phe, X is selected from the group consisting of Gin, Ser, Thr, Cit, and Arg, Y is selected from the group consisting of Leu, He, and Val, Z is selected from the group consisting of Gly and Ala; and the following vasopressin derivatives: wherein W is selected from the group consisting of He, Phe, Cha, Val, and Hoph, X is selected from the group consisting of Gin, Cit, Arg, and Daba, Y is selected from the group consisting of Arg, Hos, Daba, and Cit, Z is selected from the group consisting of Gly and Ala. 8. Composition according to Claim 4-5 and 7, characterized in that the substance is selected from the group consisting of the following oxytocin derivatives: oxytocin, mesotocin, isotocin, Peptide 2, Peptide 3, Peptide 4, and Peptide 8; and the following vasopressin derivatives: vasotocin, vasopressin, Peptide 1, Peptide 5, Peptide 6, and Peptide 7. 9. Composition according to Claim 4, characterized in that the adjuvant is selected from the group consisting of cosmetically, particularly pharmaceutically and veterinary medicinally acceptable adjuvants, such as water and organic solvents, e.g. alcohols, especially ethanol. 10. Composition according to Claim 5, characterized in that the fragrance agent and/or the adjuvant are selected from the group consisting of hygienic and/or cosmetic products, such as eau-de-Cologne, eau-de-toilette, perfume, make-up, soap, shower cream, hair conditioning agents, such as shampoos, conditioning agents, creams, lotions, and ointments; stimulants, such as cigars, cigarettes, tobacco, and chewing-tobacco.

Inventors: LUNDEBERG THOMAS, UVNAES-MOBERG KERSTIN, LUNDEBERG, THOMAS, UVNAES-MOBERG, KERSTIN
Applicants: KAROLINSKA INNOVATIONS AB, LUNDEBERG THOMAS, UVNAES MOBERG KERSTIN, LUNDEBERG, THOMAS, UVNAES-MOBERG, KERSTIN
Application year: 1998
Main classification: A61K38
IPC codes: A61K8, A61K38, A61P43, A61Q1, A61Q5, A61Q13, A61Q19, C07K7